A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia

A. Filla, G. De Michele, G. Orefice, F. Santorelli, L. Trombetta, S. Banfi, F. Squitieri, G. Napolitano, D. Puma, G. Campanella

Research output: Contribution to journalArticle

Abstract

We performed a double-blind cross-over study with amantadine hydrochloride in 12 patients with Friedreich's disease and 2 with autosomal dominant cerebellar ataxia. Patients were randomly assigned to a placebo-amantadine or amantadine-placebo sequence. The interval between the treatments was two weeks. Patients were graded according to a functional ataxia scoring scale and videotaped in basal conditions and 90 min after a single oral dose of 100 mg amantadine or placebo. Three evaluators independently scored the videotapes. Statistical analysis showed no significant effect of amantadine in Friedreich's disease.

Original languageEnglish
Pages (from-to)52-55
Number of pages4
JournalCanadian Journal of Neurological Sciences
Volume20
Issue number1
Publication statusPublished - 1993

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Filla, A., De Michele, G., Orefice, G., Santorelli, F., Trombetta, L., Banfi, S., Squitieri, F., Napolitano, G., Puma, D., & Campanella, G. (1993). A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia. Canadian Journal of Neurological Sciences, 20(1), 52-55.